MEDIWOUND LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.24 USD | +3.28% |
|
+15.66% | +79.35% |
| Mar. 21 | MediWound Ltd. Provides Revenue Guidance for the Year 2025 and 2026 | CI |
| Mar. 21 | Transcript : MediWound Ltd., Q4 2023 Earnings Call, Mar 21, 2024 |
Presentation Operator MessageOperator (Operator)Good day, and welcome to MediWound's Third Qua...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Sector
Pharmaceuticals
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
18.24
USD
Average target price
28.5
USD
Spread / Average Target
+56.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +79.35% | 169M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- MDWD Stock
- News MediWound Ltd.
- Transcript : MediWound Ltd., Q3 2023 Earnings Call, Nov 21, 2023
